Law Daily Report

Pfizer starts dosing patients in oral COVID-19 drug trial

  • 📰 YahooSG
  • ⏱ Reading Time:
  • 27 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 14%
  • Publisher: 71%

Law Law Headlines News

Law Law Latest News,Law Law Headlines

The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop the first antiviral pill to be taken on early signs of the illness. Pfizer's mid-to-late-stage trial in 1,140 participants would study the therapy, PF-07321332, in combination with a low dose of ritonavir, which has been used with other antivirals too, the company said. To date, Gilead Sciences Inc's remdesivir, administered intravenously, is the only approved antiviral treatment for COVID-19 in the United States.

FILE PHOTO: A person walks past a Pfizer logo in New York City

The company and its rivals, including U.S.-based Merck & Co Inc and Swiss pharmaceutical Roche Holding AG, have been racing to develop the first antiviral pill to be taken on early signs of the illness. PF-07321332 is designed to block the activity of a key enzyme that is needed for the coronavirus to replicate.

Merck and partner Ridgeback Biotherapeutics' molnupiravir is already being studied in a late-stage trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in LAW

Law Law Latest News, Law Law Headlines